Altimmune Announces Patient Enrollment Begins In PERFORMA Phase 3 Trial Of Pemvidutide In MASH, Enrolling About 1,790 Patients Across Two Cohorts, 52-Week Data Expected In 2029

Benzinga Newsdesk www.benzinga.com Positive 69.4%

Neg 0% Neu 0% Pos 69.4%

Comments

No comments yet. Be the first!